Your AI-Trained Oncology Knowledge Connection!

Matthew H. Katz, MD

home / authors / matthew-h-katz-md

Articles

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

Martin C. Tom, MD;Eugene J. Koay, MD, PhD, MD Anderson Cancer Center;Priya Bhosale, MD;Prajnan Das, MD, MPH;Matthew H. Katz, MD;Jason B. Fleming, MD;Jeffrey E. Lee, MD;Gauri R. Varadhachary, MD;Robert A. Wolff, MD;Christopher H. Crane, MD
July 9th 2016

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Read More

Latest Updated Articles

RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
Published: February 11th 2025 | Updated: February 14th 2025
Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2 expert is featured in this series.
Published: December 24th 2024 | Updated: January 28th 2025
Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: January 16th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show